Development of novel pyrrolo-1,5-benzoxazepines as anti-cancer agents for the treatment of chronic myeloid leukaemia
Citation:
Sandra A. Bright, 'Development of novel pyrrolo-1,5-benzoxazepines as anti-cancer agents for the treatment of chronic myeloid leukaemia', [thesis], Trinity College (Dublin, Ireland). School of Biochemistry and Immunology, 2010, pp 245Download Item:
Bright TCD THESIS 9381 Development of.pdf (PDF) 106.7Mb
Abstract:
Chronic myeloid leukaemia (CML) is characterised by the presence of a
constitutively active tyrosine kinase known as Bcr-Abl. The Bcr-Abl kinase inhibitor,
STI571, is the first line treatment for CML, but the recent emergence of STI571 resistance
has led to the search for alternative drug treatments and the examination of combination
therapies for CML. The recently developed novel set of compounds, the pyrrolo-1,5-
baizoxazepines, (PBOXs), can be subdivided into two groups with distinct mechanisms of
action, G1 -arresting agents and apoptosis-inducing compounds. In this report, we sought to
analyse the effect of various representative PBOX compounds alone and in combination
with anti-cancer agents on CML cells.
Author: Bright, Sandra A.
Advisor:
Zisterer, DanielaQualification name:
Doctor of Philosophy (Ph.D.)Publisher:
Trinity College (Dublin, Ireland). School of Biochemistry and ImmunologyNote:
TARA (Trinity’s Access to Research Archive) has a robust takedown policy. Please contact us if you have any concerns: rssadmin@tcd.ieType of material:
thesisAvailability:
Full text availableKeywords:
Biochemstry, Ph.D., Ph.D. Trinity College Dublin.Licences: